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Abstract 
An attractive herbal product, softgel capsules containing 10 mg of Echinacea angustifolia 
lypophylic extract, was given in a single oral administration to 10 human voluntaries to perform a 
pharmacokinetic and immunological study.  
The plasma concentration of the major constituent was monitored, quantifying at predetermined 
time points the dodeca-2E,4E,8Z,10E/Z-tetraenoic isobutylamides (tetraene). The plasmatic levels 
of IL-2, IL-6, IL-8, IL-10 and TNF-a in samples collected before and 24 h after drug administration 
were analyzed by cytokine assay. The total RNA was extracted from limpho-monocyte isolated 
from the same blood samples and the same cytokines in term of gene expression were evaluated. 
With the help of proper statistical tests the differences between the values obtained at 0 and 24 h 
were evaluated. 
Results of pharmacokinetic studies attest an approximately 3.5-fold improvement of tetraene oral 
bioavailability compared with previously published studies. Dodeca-2E,4E-dienoic acid 
isobutylamide exerts immunomodulatory effects down-regulating the gene expression and reducing 
the protein plasmatic levels of pro-inflammatory cytokines such as IL-6, TNF-α and IL-8, and up-
regulating the expression of anti-inflammatory molecules as IL-10. Student's two-sided paired t-
test and non-parametric Wilcoxon-Mann-Whitney signed rank test agree in the conclusions about 
the differences between the ln values at 24h and corresponding ln values at 0h. 
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Introduction 
The historical and popular tradition of the medicinal use of Echinacea is related to the three 
most relevant species, E. pallida, E. purpurea and E. angustifolia. Nowadays, in developed 
countries products containing Echinacea are very common in pharmacies, grocery or health-food 
  
stores, and hundreds of different commercial preparations are available. Independently of the kind 
of extract or preparation, Echinacea is considered as an enhancer of the immune response and its 
main indications are the prevention and treatment of common cold, flu and upper respiratory tract or 
lower urinary tract infections (Blumenthal et al., 1998). Four major groups of compounds contained 
in Echinacea preparations may be responsible for the immune response stimulation: the 
phenylpropanoids related to caffeic acid derivatives (caftaric acid, cynarine, cichoric acid and 
echinacoside), the alkylamides (2-ene and 2,4-diene), glycoproteins and polysaccharides (Bauer, 
1999). 
In spite of numerous new studies, the therapeutic effect of echinacea species cannot be 
clearly attributed to one specific class of constituents. However, previously published in vivo data in 
humans suggest that the alkamides, in particular the major alkamide, dodeca-2E,4E,8Z,10E/Z-
tetranoic acid isobutylamide (tetraene), play a very important role due to their numerous 
immunomodulatory and anti-inflammatory properties, by modulation of macrophages and PMN 
immune cells and cytokine/chemokine expression (Woelkart et al., 2005a; Woelkart et al., 2006; 
Guiotto et al., 2008). 
Since Echinacea alkamides are clinically relevant ingredients, an appropriate standardization 
of their content and a suitable formulation allowing their stability and absorption must be 
warranted. Biopharmaceutical and pharmacokinetic data are primarily important to link results from 
in vitro assays to clinical studies, and hence to establish pharmacologically relevant blood levels. 
Data concerning the absorption, metabolism, the bioavailability, and bioactivity of such natural 
products and their metabolites after oral administration have been available only recently. The 
results of the studies are frequently contradictory due to the different compositions and different 
formulations (e.g. tinctures, tablets, bonbons, throat sprays) of the applied preparations (Dietz et al., 
2001; Matthias et al., 2005; Woelkart et al., 2006; Matthias et al., 2007; Guiotto et al., 2008; 
Woelkart et al., 2008; Gurley et al., 2008).  
  
For better stabilisation and absorption of the active Echinacea alkamides, in the present 
study, softgel capsules containing Echinacea angustifolia lypophylic extract with a well-defined 
content of actives (alkamides) have been prepared and administered to healthy voluntaries with the 
aim of evaluating both the major alkamide bioavailability and the immune response after single 
dose oral administration. 
Material and methods 
Echinacea angustifolia lypophylic extract (Echinamid®, Indena Milan, Italy) formulated in softgel 
capsules by Pharmagel Engineering S.p.A. (Lodi, Milano, Italy) was tested. Each capsule (weighing 
24 mg) contained 10 mg of above mentioned extract corresponding to a dose of 1 mg dodeca-
2E,4E,8Z,10E/Z-tetraenoic isobutylamides. The capsules also contain the following inactive 
ingredients: gelatin, glycerin, titanium dioxide, iron oxide yellow.  
Reagents 
 Acetonitrile (HPLC grade, Rotisolv) and Tris buffer (Pufferan) were from Carl Roth 
GmbH+Co. (Karlsruhe, Germany). A Barnstead (easy pure RF) compact ultrapure water 
purification system was used to obtain the purified water for HPLC analysis. Acetonitrile, formic 
acid and methanol were from BDH (Liverpool, UK), Tris buffer (Tris-d11, 99% D) and benzanilide 
(98%) from Aldrich (Milan, Italy).  
 
Study design 
10 healthy voluntaries of both genders (6 males, 4 females) between 26 and 53 years of age 
participated in this single blind study. All the volunteers were with normal liver function and 
without diagnosed allergy or sensitivity to Compositae or Grossolariaceae plants. None of the 
voluntaries was on a special diet. No medicines were taken during the study and the voluntaries 
were asked not to smoke and nor eat, and drink only water for 12 h before administration. All 
subjects gave their written consent to participate in this study. Each of them was administered a 
single softgel capsule containing 1 mg of dodeca-2E,4E,8Z,10E/Z-tetraenoic isobutylamides, orally 
  
after an overnight fasting. Blood samples (5 mL) collected in heparinised tubes were taken at 0 
(before administration) and at 15, 30, 45, 60, 90, 120, 180, 240, and 300 min after each dose. 
Plasma was separated by centrifugation and stored frozen at -80°C for analysis. In each period 
subjects were abstinent from smoking, eating and drinking until the last blood sample was taken. 
The study was conducted in compliance with the Declaration of Helsinki and the International 
Conference on Harmonization Guidelines at the University of Trieste, Italy and the protocol was 
approved by the University of Trieste Human Research Ethics Committee. 
Blood samples (2 x 5 mL) collected in EDTA-tubes were taken once a week on days -35, -28,- 21, -
14, -7, 0, 7,14, 21, 28 (for a total of 10 blood sampling). After sample withdrawal, one mL of 
plasma was immediately separated by centrifugation and frozen at -80°C for subsequent cytokine 
analysis assay. Within 4 h after blood withdrawal from 5 mL of complete blood, lympho-monocytes 
were isolated by Ficoll-Paque™ method introduced by Bøyum (1968) and already employed in our 
previous work (Dapas et al., 2014). 
 
Plasma samples preparation 
The plasma samples were extracted using a solid-phase extraction technique (Woelkart et 
al., 2005a; Guiotto et al., 2008). Briefly, to 2 mL of plasma 2 mL of Tris buffer and 100 µL of 
benzanilide solution, used as internal standard (I.S.), were added and vortexed for 1 min. 
Subsequently, samples were centrifuged for 10 minutes at 3,200 rpm using Eppendorf centrifuge 
5810R (Hamburg, Germany). The supernatant was applied onto C18, 100 mg Isolute columns from 
International Sorbent Technology (Mid Glamorgan, UK), pre-treated with 1 reservoir volume (RV) 
acetonitrile followed by 1 RV water. The C18 cartridges were placed on a VacMaster sample 
processing station and subsequently washed with 1 RV of water under vacuum. The dodeca-
2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides were eluted with 2 mL acetonitrile. The eluents 
were evaporated under a stream of nitrogen at 40°C using TurboVab LV vaporator (Zymark, 
  
Hopkinton, MA, USA), the dry residue was dissolved in 100 µL acetonitrile:water (6:4) and 20 µL 
were used for LC/MS analysis. 
 
LC-MS-MS analysis 
Alkamides concentrations in samples were determined by LC/MS analysis as previously 
described by Woelkart et al. (2005a) using LC-ESI-IT-MS/MS composed of Varian 212 binary 
chromatograph equipped with a Prostar 430 thermostatic authosampler and Varian 500 ion trap 
mass spectrometer  with Varian Workstation software. Gradient elution was used using acetonitrile 
with 0.1% formic acid and water with 0.1% formic acid 40/60 (v/v) to 80/20 (v/v) in 13 min. As 
stationary phase a Zorbax SB-C18 Narrow Bore 2.1 x 150 mm 3.5 µm column from Agilent 
Technologies was used at a flow rate of 200 µL/min. For MS detection ESI interface operating in 
positive Ion mode was used. The source voltage was set at 4.8 kV, vaporizer temperature at 300°C, 
nebulizer gas pressure was at 15 psi and helium gas for collision. ForSRM (single reaction 
monitoring) mass transition m/z 248  m/z 149 was used for quantification of dodeca-
2E,4E,8Z,10E/Z-tetraenoic isobutylamides. The analytical procedure was validated by analysis of 
quality control samples. Calibration curves were obtained by plotting the dodeca-2E,4E,8Z,10E/Z-
tetraenoic isobutylamides/I.S. (Benzamide) peak area versus the known spiked plasma 
concentration of the analyte. Limit of detection was at 0.1 ng mL-1. Linearity was obtained in the 
range of 0.3–80 ng mL-1.  
 
Pharmacokinetics analysis 
Non-compartmental pharmacokinetic analysis was performed using WinNonlin Version 2.1 
software from Pharsight Corporation (Mountain View, CA). Time and value of maximum 
concentration (tmax and Cmax, respectively) were reported as observed. Terminal half-life (t1/2) was 
calculated as t1/2 = ln2 / λz, where λz is the terminal slope of the plasma concentration profile on the 
semi-log plot calculated by linear regression. The area under the concentration-time curve (AUC) 
  
was calculated using the linear trapezoidal method and extrapolated to infinity (AUCinf) as AUC + 
Clast/λz, where Clast is the last measurable concentration. Mean residence time (MRT) was calculated 
as AUMCinf/AUCinf, where AUMCinf is the area under the first moment curve. Since fraction of the 
dose absorbed (F) cannot be estimated based solely on the data after extravascular administration, 
apparent clearance (CL/F), calculated as Dose/AUCinf, and apparent volume of distribution based 
on terminal phase (Vz/F), calculated as CL/F/λz, are reported. 
 
Cytokine analysis 
The levels of 48 cytokines (in particular, the attention was paid to IL-2, IL-6, IL-8, IL-10 and TNF-
α), in plasma samples collected before and 24 h after drug administration, were analysed using two 
Bio-Plex cytokine assay panels (the pro-human cytokine 27-Plex M50-0KCAF0Y and 21-Plex 
MF0-005KMII, both from Bio-Rad, Hercules, CA) as recently reported (Comar et al., 2014). The 
samples were analyzed following the manufacturer’s instructions using the BioPlex 100 Analyzer 
(Bio-Rad Laboratories).  
Quantitative PCR 
Total RNA was extracted, quantified and the quality evaluated as described (Baiz et al., 2009). 
Reverse transcription was performed using 500 ng of total RNA in the presence of random examers 
and MuLv reverse transcriptase (Applera Corporation, USA). To detect the mRNA levels of the 
cytokines IL-2, IL-8, IL-6 and TNF-α, Real-Time polymerase chain reaction was performed as 
described (Baiz et al. 2009). The primers (MWG Biotech, GA, USA, 300 nM) and the annealing 
temperatures used are reported in Table 1. The relative amounts of each target mRNA was 
normalized by 28S rRNA content according to Pfaffl (2004). 
Statistical analysis 
Statistical analyses were performed using R version 3.1.2 (R Core Team, 2014). The Shapiro-Wilk 
test rejected normality for some of the samples. Therefore, both mRNA values and plasmatic 
concentrations were transformed by taking their natural logarithm (ln). Actually, the lognormal 
  
distribution of mRNA levels is a well consolidated result (Bengtsson et al., 2005).  The differences 
between the ln values at 24h and corresponding ln values at 0h were evaluated by Student's two-
sided paired t-test. Taking into account the size of our sample (n = 10 voluntaries), we also applied 
the non-parametric Wilcoxon-Mann-Whitney (WMW) signed rank test in its "exact" combinatoric 
form without normal approximation (Hothorn and Hornik, 2013).  
 
Results and discussion 
Pharmacokinetic study 
Some of the in vivo immumomodulating effects of the extracts of the roots of E. angustifolia are 
likely caused by the fat-soluble alkylamides (alkamydes), as reported in the recent years by several 
authors (Dietz et al., 2001; Matthias et al., 2005 and 2007; Guiotto et al., 2008; Woelkart et al., 
2005a, 2006, 2008). Nevertheless up to now limited information have been published considering 
both the biological effects and the alkilamide pharmacokinetics. Within this aim, in this research 
softgel capsules formulated lipophilic extract was administered to 10 healthy voluntaries and 
pharmacokinetics was studied, quantifying at predetermined time points the plasma concentration of 
the major constituent, namely, dodeca-2E,4E,8Z,10E/Z-tetraenoic isobutylamide (tetraene) as 
suggested in some previous studies (Woelkart et al. 2005a, 2006; Guiotto et al., 2008). It has now 
been known for many years that softgel formulation can ameliorate the pharmacokinetic profiles of 
certain pharmaceutical drugs and natural products (e.g. silybin, Coenzyme Q10 and Hypericum 
perforatum extracts) (Agrosì et al., 2000).  
Mean time course of dodeca-2E,4E-dienoic acid isobutylamide concentration is presented in Figure 
1. Results of the non-compartmental pharmacokinetic analysis are summarized in Table 2.  
In agreement with the high permeability in the Caco-2 cells absorption model (Jager et al., 2002; 
Matthias et al., 2004) dodeca-2E,4E-dienoic acid isobutylamide was very rapidly absorbed. Time of 
maximum plasma concentration ranged between 0.25 and 2 h. In five out of ten subjects maximum 
plasma concentration was observed already after the first blood draw, 15 min after drug 
  
administration. A double-peak phenomenon was evident from the individual pharmacokinetic 
profiles. Typically, the first peak concentration at 15 min was followed by a second peak at about 1 
hour. This may be associated with the micellization of the alkamydes, previously demonstrated by 
Raduner et al. (2007). Evaluation of the results of previous pharmacokinetic studies with Echinacea 
extract, Echinacea extract tablets, throat spray, and Echinacea bonbons (Dietz et al., 2001; Matthias 
et al., 2005; Woelkart et al., 2006; Matthias et al., 2007; Guiotto et al., 2008; Woelkart et al., 2008) 
containing various doses of dodeca-2E,4E-dienoic acid isobutylamide (ranging from 0.07 to 17.16 
mg) reveals more than proportional increase in AUC with the increase in the dose, indicating 
nonlinear pharmacokinetics. The relationship between dose normalized tetraene AUC and dose is 
approximately linear (Fig. 2). Comparison of AUC/Dose of softgel capsules evaluated in the current 
study (mean: 16.93 ng × h/mL/mg; 95% CI: 15.33-18.53 ng × h/mL/mg) with the 95% prediction 
interval from the previous studies indicates significant 3.5-fold improvement in bioavailability of 
tetraene with this type of formulation. 
Immunological in vivo study 
The results corroborate the hypothesis that the alkamides can be easily absorbed and, hence, may 
contribute to the in vivo effects of echinacea preparation. Furthermore, receptor binding studies to 
cannabinoid type 1 and 2 receptors (CB1 and CB2) were carried out to demonstrate the molecular 
mode of action and highlight the role of the alkamides as potent immune-modulators (Raduner et 
al., 2006; Gertsch et al., 2004; Woelkart  et al., 2005b). 
Student's two-sided paired t-test and non-parametric Wilcoxon-Mann-Whitney (WMW) signed rank 
test agree in the conclusions about the differences between the ln values at 24h and corresponding 
ln values at 0h. In all cases we got p-values < 0.05, that is, the treatment has a statistically 
significant effect both on the mRNA values and the plasmatic concentrations. In particular, the 
treatment decreases the values of interest, with the single exception of the mRNA for IL-10, which, 
instead, increases. 
  
The ln data were graphically presented as boxplots  (Figure 3 and 4), where whiskers extend to the 
data extremes; the arrows join paired data. The significant stars code is 0 < *** ≤ 0.001 < ** ≤ 0.01 
< * ≤ 0.05. Fig. 5 presents the 95% CI's. The CI's estimated by the t-test are centred at the means of 
differences marked with a triangle-down symbol, while the CI's given by the WMW test are 
(usually asymmetrically) located at the (pseudo) medians of the same differences, marked triangle-
up. The agreement of the parametric and the non-parametric CI's is neatly satisfactory, and so both 
tests jointly support our conclusions.  
As regards to the dodeca-2E,4E-dienoic acid isobutylamide immunomodulatory effects via 
cytokines expression, a down-regulation of mRNA and plasmatic level of IL-2, a potent interleukin 
necessary for the growth, proliferation, and differentiation of T cells (Smith, 1988) were observed. 
Our data are in accordance with Sasagawa and colleagues (2006) that reported the capability of 
Echinacea alkylamides to suppress the expression by Jurkat T cells of IL-2. This observation 
indicates that the intake of Echinacea extract may inhibit the adaptive immune response, acting on 
the activation of lymphocyte cells. 
In this case, the anti-inflammatory effect of dodeca-2E,4E-dienoic acid isobutylamide is also 
manifested by the down-regulation, both in terms of gene and protein expression, of IL-6 and TNF-
α, two cytokines principally responsible for systemic inflammation (Jones, 2005). IL-6 and TNF-α 
are pro-inflammatory cytokine, produced by professional antigen-presenting cells (macrophages, B 
cells and DC). Their activity is crucial for the management of acute inflammation and subsequent 
resolution, but they are also associated with chronic inflammatory diseases (Jones, 2005). Our data 
are in agreement with Cech et al. (2010) that observed that dodeca-2E,4E-dienoic acid 
isobutylamide suppressed the production of TNF-α by macrophages-like cell. Gertsch et al. (2004) 
reported on the potent modulatory action of Echinacea alkylamides on TNF-α expression in human 
monocytes/macrophages. It was shown that this effect is mediated via CB2 cannabinoid receptor. 
Raduner and colleagues (2006) showed that tetraene bind CB2 receptor more strongly than the 
endogenous cannabinoids. But in contrast with our data, they observed an up-regulation of IL-6. 
  
These evidences indicate that Echinacea extracts may reduce the inflammatory response and act 
also on the innate immune-response. 
In agreement with our results, in 2006 Woelkart and coauthors demonstrated that the intake of 
Echinacea purpurea preparation (23 h after oral application) led to a significant down-regulation of 
TNF-α and IL-8 in LPS pre-stimulated whole blood. Also our data indicates a down regulation, by 
Echinacea extract intake, of the gene expression and synthesis of plasmatic protein of IL-8, a 
chemokine produced by endothelial cells and macrophages, that promotes the neutrophil migration 
and leukocytes arrest (Sprague and Khalil, 2009). All this information confirm dodeca-2E,4E-
dienoic acid isobutylamide anti-inflammatory action. 
There is good evidence that constitutive TNF-α is inhibited by the endocannabinoid system and that 
the CB2 receptor is involved (Rajesh et al., 2008; Mechoulam and Shohami, 2007). The CB2 
agonists dose-dependently attenuate the effects of TNF-α. TNF-α triggers the activation of Ras, p38 
MAPK, ERK1/2, SAPK/JNK and Akt pathways and ultimately pro-inflammatory cytokine 
expression and cellular proliferation and migration. On the other hand, activation of the CB2 
receptor by agonists in macrophages has been shown to activate Erk1/2 which leads to expression 
of IL-10 and thus a counteraction to pro-inflammatory gene expression (Gertsch, 2009). IL-10 is the 
typical anti-inflammatory cytokine, produced by macrophages (in particular M2), T lymphocytes 
(Th2 and Treg) and B-cells. It inhibits the pro-inflammatory cytokines production and the Th1 (and 
M1) response (Sprague and Khalil, 2009). 
Also our data indicates that IL-10 gene is up-regulated by CB2 agonist, but unexpectedly this 
increase is not correlated with an augmentation of the plasmatic level of this anti-inflammatory 
cytokine. Maybe this difference is due to a delay of the response at the systemic/peripheral tissue 
level by wide variety of cells, responsible of the synthesis of the plasmatic cytokine IL-10. 
Conclusions 
  
In this pilot study, 10 human voluntaries have been treated with a new herbal product: softgel 
capsules containing 10 mg of Echinacea angustifolia lypophylic extract, corresponding to a dose of 
1 mg dodeca-2E,4E,8Z,10E/Z-tetraenoic isobutylamides (tetraene). Results of the present 
pharmacokinetic study confirm that softgel capsules containing lipophylic Echinacea extract are an 
attractive formulation to improve bioavailability of tetraene. It was estimated that improvement is 
approximately 3.5-fold compared with previous studies with other tetraene formulations. However, 
pharmacokinetics of the reference formulations has not been compared directly, which is a 
limitation of the present study. The effect on bioavailability of tetraene has to be confirmed in 
future studies. Additionally, this study demonstrates the effect on the innate and adaptive immune-
system of Echinacea angustifolia lypophylic extract in healthy subjects, supporting at least in part 
its use as health promoting supplement. Indeed this treatment has potentially a strong anti-
inflammatory effect reducing the synthesis and plasma levels of powerful pro-inflammatory 
cytokines such as IL-6, TNF-α and IL-8 and up-regulating the expression of anti-inflammatory 
molecules as IL-10. 
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Figure Legends 
Figure 1: Mean (±SD) time course of dodeca-2E,4E-dienoic acid isobutylamide concentration in 
plasma in 10 healthy volunteers following oral administration of lipophilic Echinacea extract 
formulated as soft gelatine capsules (dose 1 mg).  
Figure 2.  
Dose dependency of dodeca-2E,4E-dienoic acid isobutylamide bioavailability. The data on 
bioavailability were extracted from previous pharmacokinetic studies with various formulations of 
Echinacea extract. This analysis demonstrates that the increase in AUC/Dose with Dose is 
approximately linear (regression line and 95% prediction interval). Error bars with Soft gel caps 
indicate 95% confidence interval. 
  
Figure 3 Box‐and‐whisker chart for the ln of mRNA/28S observed data at time t = 0h and t = 24h. 
The whiskers extend to the data extremes; the arrows join paired data. The p-values refer to the 
paired Student's t-test and to the paired non-parametric Wilcoxon-Mann-Whitney (WMW) signed 
rank test in its "exact" combinatoric form. The significant stars code is 0 < *** ≤ 0.001 < ** ≤ 0.01 
< * ≤ 0.05.  
Figure 4 Box‐and‐whisker chart for the ln of plasmatic observed data (pg/ml) at time t = 0h and t = 
24h. The whiskers extend to the data extremes; the arrows join paired data. The p-values refer to the 
paired Student's t-test and to the paired non-parametric Wilcoxon-Mann-Whitney (WMW) signed 
rank test in its "exact" combinatoric form. The significant stars code is 0 < *** ≤ 0.001 < ** ≤ 0.01 
< * ≤ 0.05.  
Figure 5 95% CI's for differences h24-h0 of mRNA/28S and plasmatic levels (ln scaled).  The CI's 
estimated by the t-test are centered at the means of differences, marked with a triangle-down, while 
those given by the WMW test are located at the pseudo-medians of the same differences, and are 
marked with a triangle-up.   
 
  
  
 
 
